Compare
SAB Biotherapeutics, Inc. vs Sutro Biopharma, Inc. vs Caribou Biosciences, Inc. vs Vaxart, Inc.
| Latest fiscal year | SAB Biotherapeutics, Inc. SABSRevenue covers only part of its income (partial revenue) | Sutro Biopharma, Inc. STRO | Caribou Biosciences, Inc. CRBU | Vaxart, Inc. VXRT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $102.48M | $11.16M | $237.26M |
| Revenue growth (YoY) | n/a | +65.2% | +11.7% | +726.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -154.5% | n/m | 7.6% |
| Net margin | n/a | -186.5% | n/m | 6.9% |
| Net income | $13.27M | -$191.09M | -$148.12M | $16.33M |
| EPS (Diluted) | -$0.79 | -$22.49 | -$1.59 | $0.07 |
| Operating cash flow | -$44.78M | -$177.23M | -$110.99M | $7.71M |
| Free cash flow | -$45.71M | n/a | -$112.35M | $7.57M |
| Cash & equivalents | $10.50M | $58.13M | $12.36M | n/a |
| Total assets | $172.81M | $173.83M | $175.37M | $186.08M |
| Total liabilities | $21.32M | $306.28M | $53.19M | $98.28M |
| Shareholders' equity | $151.49M | -$132.45M | $122.17M | $87.80M |
| Return on year-end equity | 8.8% | n/a | -121.2% | 18.6% |
| Shares outstanding | 47.61M | 8.58M | 95.14M | 240.49M |
Revenue, most recent five fiscal years
| Fiscal year | SAB Biotherapeutics, Inc. | Sutro Biopharma, Inc. | Caribou Biosciences, Inc. | Vaxart, Inc. |
|---|---|---|---|---|
| Latest | n/a | $102.48M Ended 2025-12-31 | $11.16M Ended 2025-12-31 | $237.26M Ended 2025-12-31 |
| 1 year earlier | n/a | $62.04M Ended 2024-12-31 | $9.99M Ended 2024-12-31 | $28.70M Ended 2024-12-31 |
| 2 years earlier | n/a | $153.73M Ended 2023-12-31 | $34.48M Ended 2023-12-31 | $7.38M Ended 2023-12-31 |
| 3 years earlier | n/a | $67.77M Ended 2022-12-31 | $13.85M Ended 2022-12-31 | $107.0K Ended 2022-12-31 |
| 4 years earlier | n/a | $61.88M Ended 2021-12-31 | $9.60M Ended 2021-12-31 | $892.0K Ended 2021-12-31 |